MX2022014520A - Preparacion y purificacion de igg hipersialilada. - Google Patents

Preparacion y purificacion de igg hipersialilada.

Info

Publication number
MX2022014520A
MX2022014520A MX2022014520A MX2022014520A MX2022014520A MX 2022014520 A MX2022014520 A MX 2022014520A MX 2022014520 A MX2022014520 A MX 2022014520A MX 2022014520 A MX2022014520 A MX 2022014520A MX 2022014520 A MX2022014520 A MX 2022014520A
Authority
MX
Mexico
Prior art keywords
hypersialylated
igg
purification
preparation
purifying
Prior art date
Application number
MX2022014520A
Other languages
English (en)
Spanish (es)
Inventor
John Schaeck
Steffen Graham
Radouane Zouaoui
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MX2022014520A publication Critical patent/MX2022014520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2022014520A 2020-05-19 2021-05-19 Preparacion y purificacion de igg hipersialilada. MX2022014520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063026875P 2020-05-19 2020-05-19
PCT/US2021/033156 WO2021236769A1 (en) 2020-05-19 2021-05-19 Preparation and purification of hypersialylated igg

Publications (1)

Publication Number Publication Date
MX2022014520A true MX2022014520A (es) 2023-03-03

Family

ID=78708028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014520A MX2022014520A (es) 2020-05-19 2021-05-19 Preparacion y purificacion de igg hipersialilada.

Country Status (11)

Country Link
US (1) US20230193339A1 (https=)
EP (1) EP4153617A4 (https=)
JP (1) JP2023526527A (https=)
KR (1) KR20230012560A (https=)
CN (1) CN115715296A (https=)
AU (1) AU2021275117A1 (https=)
BR (1) BR112022023377A2 (https=)
CA (1) CA3182023A1 (https=)
CO (1) CO2022018364A2 (https=)
MX (1) MX2022014520A (https=)
WO (1) WO2021236769A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022023334A2 (pt) * 2020-05-19 2022-12-20 Momenta Pharmaceuticals Inc Imunoglobulina hipersialilada

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113604A2 (en) * 2004-05-14 2005-12-01 Hematech, Llc Methods for immunoglobulin purification
PH12012502193A1 (en) * 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
AU2011290672B2 (en) * 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
EP2877589B1 (en) * 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
EP2935610A4 (en) * 2012-12-20 2016-08-31 Medimmune Llc METHODS OF USING ION EXCHANGE CHROMATOGRAPHY TO CONTROL GLYCOFORM RATES WITH HIGH MANNOSIS
WO2014144621A2 (en) * 2013-03-15 2014-09-18 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
CN104327180A (zh) * 2013-07-23 2015-02-04 天士力制药集团股份有限公司 一种重组人血小板衍生生长因子bb的纯化方法

Also Published As

Publication number Publication date
JP2023526527A (ja) 2023-06-21
CA3182023A1 (en) 2021-11-25
CN115715296A (zh) 2023-02-24
AU2021275117A1 (en) 2022-12-01
BR112022023377A2 (pt) 2022-12-20
CO2022018364A2 (es) 2022-12-30
EP4153617A1 (en) 2023-03-29
KR20230012560A (ko) 2023-01-26
EP4153617A4 (en) 2024-11-20
US20230193339A1 (en) 2023-06-22
WO2021236769A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2020013583A (es) Anticuerpos il-11.
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
JOP20230312A1 (ar) أجسام مضادة لـ ccr8 واستخداماتها
EA202092605A1 (ru) Антитела к ил-11ra
EP4691569A3 (en) Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
EP4157272C0 (en) REMDESIVIR FOR THE TREATMENT OF VIRAL INFECTIONS
JOP20230311A1 (ar) أجسام مضادة لـ sirp-ألفا
EP3978102A4 (en) Forward osmosis membrane, forward osmosis membrane module, and manufacturing method thereof
MX2020010724A (es) Metodos para preparar composiciones proteicas estables.
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
MX2022010542A (es) Composiciones y metodos para reducir la expresion de citocinas.
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
CL2021003036S1 (es) Par de auriculares.
EP3946373A4 (en) ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 FOR TREATING BLOOD CANCER
EP4436667C0 (en) PIPERAZINYLSULFONYLARYL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
EP4440574A4 (en) USE OF PIPENDOXIFEN TO TREAT SARS-CoV-2 INFECTION
CL2020003458S1 (es) Auriculares.
MX2022014520A (es) Preparacion y purificacion de igg hipersialilada.
JOP20230034A1 (ar) مثبطات إفراز البروتين
EA202191779A1 (ru) Способ получения антраниламидов
GB202020502D0 (en) Antibody composistion for treatment of corona virus infection
IL281447A (en) Methods and compositions for treating viral infections
MX2024005962A (es) Composiciones de proteínas de fusión inmunogénicas y métodos de uso de estas
EP4387994A4 (en) IGA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION
EA202092675A1 (ru) Фармацевтические комбинации